|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | Other Dementias | | | | | | | No dementia | | | |
|  | **Uncertain diagnosis** | **DLB** | **FTLD** | **VaD** | **PSP** | **CBD** | **NPH** | **CJD** | **MCI** | **SMC** | | **PSY** |
| **N (%)** | 120  (10.5%) | 65  (5.7%) | 53  (4.7%) | 31  (2.7%) | 21  (1.9%) | 14 (1.2%) | 218 (19.2%) | 30  (2.6%) | 52  (4.6%) | 230 (20.2%) | 37  (3.3%) | |
| **Women\*\*** | 51.7% | 23.1% | 47.2% | 41.9% | 52.4% | 35.7% | 43.1% | 30.0% | 50.0% | 53.5% | 43.2% | |
| **Age\*** | 65.28  (13.54) | 73.14  (7.86) b | 63.62  (8.78) | 70.19 (8.9) | 69.82 (10.5) | 67.73 (12.7) | 76.79 (8.0) | 66.99  (9.9) | 70.19  (8.27) | 61.79 (15.6) c | 59.65  (13.55) b | |
| **Deaths \*\*** | 8.33% | 9.23% | 11.32% | 12.90% | 9.52% | 14.28% | 5.04% | 90.00% | 0.00% | 9.13% | 0.00% | |
| **Edu\*** | 15.64  (4.7) | 17.00  (3.6) | 16.91  (4.1) | 14.00 (6.3) | 15.33 (2.7) | 14.67 (3.06) | 15.40 (2.95) | 14.00  (2.83) | 17,52  (3.5) | 16.60 (3.42) | 17.20  (3.51) | |
| **Aβ42\*** | 503.58  (272.5) c | 501.76 (280.02) c | 617.88  (291.22) c | 458.52 (253.22) | 642.90(244.37) c | 542.67 (231.62) | 424.23 (220.03) | 502.21 (304.40) | 561.94  (206.2) c | 493.26 (299.66) c | 580.92 (236.09) c | |
| **tTau\*** | 460.17  (530.8) | 235.98 (138.42) | 295.53 (138.38) | 906.48 (2014.30) | 294.63 (151.62) | 269.77 (120.03) | 425.33 (553.96) | 4177.74 (4099.1) c | 358.39  (293.25) | 458.44 (997.53) | 207.56  (88.18) | |
| **pTau\*** | 54.08  (30.72) c | 43.10  (18.12) c | 44.63 (15.46) c | 43.70 (20.86) c | 49.45 (14.65) c | 44.67 (15.71) c | 42.11 (27.86) c | 49.72 (25.44) c | 57.96  (24.36) c | 41.39 (32.22) c | 40.25  (13.64) c | |
| **ATI\*** | 0.91  (0.65) c | 1.01  (.053) c | 1.10  (0.53) c | 0.74  (.056) | 1.19  (0.56) c | 1.08 (0.58) c | 0.82 (0.55) c | 0.33  (0.71) | 1.02  (0.52) c | 0.98  (0.68) c | 1.24  (0.53) c | |

**Supplementary Table 1**

**\***

Percentages refer to the total amount of patients (n=1,137) who underwent CSF biomarker measurements. DLB, dementia with Lewy bodies; FTLD, frontotemporal lobar dementia; VaD, vascular dementia; PSP, progressive supranuclear palsy; CBD, corticobasal degeneration; NPH, normal pressure hydrocephalus; CJD, Creutzfeldt-Jacob disease; MCI, mild cognitive impairment; SMC, subjective memory complaints; PSY, psychiatric disorders. Step-wise comparison of variance between Alzheimer’s disease and diagnostic groups.

ap value <0.05. bp value <0.01. cp value < 0.0001. Tests are adjusted for all pairwise comparisons within a row of each innermost subtable using the Bonferroni correction. \*Kruskall Wallis test was used for comparing means across continuous nonstandard distributed variables. \*\*Chi-square test was used for comparing means across dichotomized variables

**Supplementary Table 2**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **CSF Biomarkers** | **MCI (n=52)** | | | **FTLD (n=53)** | | | **DLB (n=65)** | | | **VaD (n=31)** | | | **CJD (n=30)** | | |
|  | **AUC** | **Sens** | **Spec** | **AUC** | **Sens** | **Spec** | **AUC** | **Sens** | **Spec** | **AUC** | **Sens** | **Spec** | **AUC** | **Sens** | **Spec** |
| **Aβ42 > 500 pg/ml** | 0.781 | 0.814 | 0.71 | 0.612 | 0.814 | 0.400 | 0.756 | 0.81 | 0.604 | 0.568 | 0.814 | 0.387 | 0.579 | 0.814 | 0.400 |
| **tTau > 350 pg/ml** | 0.751 | 0.77 | 0.577 | 0.885 | 0.767 | 0.877 | 0.817 | 0.767 | 0.717 | 0.643 | 0.767 | 0.613 | < 0.5 | // | // |
| **pTau > 61 pg/ml** | 0.718 | 0.73 | 0.558 | 0.868 | 0.729 | 0.913 | 0.859 | 0.729 | 0.868 | 0.834 | 0.729 | 0.839 | 0.812 | 0.729 | 0.828 |
| **ATI < 1** | 0.834 | 0.97 | 0.481 | 0.834 | 0.966 | 0.400 | 0.861 | 0.966 | 0.566 | 0.627 | 0.970 | 0.258 | < 0.5 | // | // |
| **ATI < 1 + pTau>61** | 0.833 | 0.788 | 0.80 | 0.911 | 0.907 | 0.801 | 0.917 | 0.867 | 0.83 | 0.844 | 0.838 | 0.759 | 0.909 | 0.793 | 0.908 |

The table shows area under the curve (AUC), sensitivity (Sens), and specificity (Spec) for each CSF biomarkers in differentiating Alzheimer’s disease versus mild cognitive impairment (MCI), frontotemporal lobar dementia (FTLD), dementia with Lewy bodies (DLB), vascular dementia (VaD), and Creutzfeldt-Jacob (CJD). Progressive supranuclear palsy and corticobasal degeneration were excluded because of their sample size. Normal pressure hydrocephalus was examined in the paper.